Yabao Pharmaceutical Group Co. Ltd. Class A 600351
SSE · China · Health Technology
CNY 6.82+0.12 (+1.79%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that China's National Medical Products Administration has approved its Abbreviated New Drug Application for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals, a leader in China's pediatric medicine market. This marks Lupin's first product entry into China — a significant milestone in its global expansion.
As Asian markets stabilize following strong economic data and limited new catalysts, investors are increasingly eyeing dividend stocks as a reliable source of income amid global uncertainties. In such an environment, a good dividend stock is often characterized by consistent payouts and the potential for steady growth, making them appealing to those seeking stability in their investment portfolios.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.